Researching Novel
Exesome & Peptide
Formulas

Therapeutic Research & Development

We are collecting and tracking the critical data of proteomics that impact health and beauty. Our research and clinical partners are committed to the same.
Contact Us

Our research and product development is FDA compliant, anchored by end to end data collection and analysis. Our novel formulas and patented laboratory processes ensure highly concentrated products that enable clinical research.

We are pursuing INDs with a range of clinical research partners. Aesthetics, inflammatory conditions, recovery, are some of the areas we are working in. Outcome data collection is a primary focus to validate the clinical relevance of our novel therapeutics.
"Our mission is to harness cellular communication pathways, with exosomes and peptides, to research and create therapeutic breakthroughs."
Dr David Crane
Founder - CEO & CMO

Our Clinical Studies

Discovery and Assessment
The journey begins with proactive search for promising medical  research projects. Our team conducts a thorough assessment,  evaluating each project's innovation, potential impact, and feasibility.  This involves rigorous scientific review, potential market  analysis, and preliminary discussions with research teams to understand  their vision, capabilities, and needs.
Upcoming Clinical Trial:
Exploring NANOVAE for Knee Osteoarthritis
Nova Vita Labs is launching a groundbreaking clinical trial to evaluate the efficacy and safety of NANOVAE – an acellular minimally manipulated allogenic human amniotic fluid-derived treatment – for patients with knee osteoarthritis (KOA). This study aims to provide new insights into non-invasive therapeutic options for managing KOA symptoms.

Learn more here

Our Products - Exosome and Peptides

Exosomes

Our investigational exosomes are derived from human amniotic fluid that are allogenic and acellular. HAF contains a wide range of growth factors, cytokines, chemokines, and extracellular vesicles/nanoparticles obtained from perinatal tissue. These components contribute to the regenerative potential of HAF and make it a promising option for regenerative medicine applications.

Our exosomes are a filtered form of HAF (human amniotic fluid) containing a wide range of nanoparticles, cytokines, and growth factors. HAF is a rich source of collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, and extracellular matrix molecules like hyaluronic acid and fibronectin.

The concentration of nanoparticles in our final product has been consistently demonstrated through nanoparticle analysis using the ZetaView Quatt nanoparticle analyzer.

Peptides

Our peptide formulations represent the cutting edge of cellular regeneration technology. We develop patented, precisely engineered, peptide sequences that target specific biological pathways, delivering concentrated therapeutic benefits where they matter most.

Key Features:

  • Highly concentrated, bioactive formulations
  • Enhanced stability and penetration
  • Optimized amino acid sequences

Potential Therapeutic Applications:

  • Cellular regeneration
  • Growth factor stimulation
  • Tissue repair and protection
  • Metabolic optimization

Our peptides are manufactured using proprietary processes that ensure maximum bioavailability. Each formulation undergoes rigorous testing to verify concentration, purity, and biological activity.

Frequently asked questions

What are exosomes?
What are peptides?